NDA 022003 · Schering
Noxafil
Posaconazole · Oral · Azole Antifungal
NovelPriority reviewLast checked: Nov 19, 2026Latest source record: Jan 27, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2006
Sep 15, 2006
Approved uses
2
Original approval plus efficacy supplements
Registered trials
90
20 Phase 3, 19 recruiting
FAERS reports
16,564
14,256 serious, 3,927 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Feb 18, 2026.
Posaconazole is an azole antifungal indicated as follows: Posaconazole delayed-release tablets are indicated for the treatment of invasive aspergillosis in adults and pediatric patients 2 years of age and older who weigh greater than 40 kg. ( 1.1 ) Posaconazole is indicated for the prophylaxis of invasive Aspergillus and Candida infections in patients who are at high risk of developing these infections due to being severely immunocompromised, such as hematopoietic stem cell transplant (HSCT) recipients with graft-versus-host disease (GVHD) or those with hematologic malignancies with prolonged neutropenia from chemotherapy as follows: ( 1.2 ) Posaconazole delayed-release tablets : adults and pediatric patients 2 years of age and older who weigh greater than 40 kg Posaconazole oral suspension: adults and pediatric patients 13 years of age and older Posaconazole oral suspension is indicated for the treatment of oropharyngeal candidiasis (OPC), including OPC refractory (rOPC) to itraconazole and/or fluconazole in adults and pediatric patients 13 years of age and older. ( 1.3 ) 1.1 Treatment of Invasive Aspergillosis Posaconazole delayed-release tablets are indicated for the treatment of invasive aspergillosis in adults and pediatric patients 2 years of age and older who weigh greater than 40 kg. 1.2 Prophylaxis of Invasive Aspergillus and Candida Infections Posaconazole is indicated for the prophylaxis of invasive Aspergillus and Candida infections in patients who are at high risk of developing these infections due to being severely immunocompromised, such as hematopoietic stem cell transplant (HSCT) recipients with graft-versus-host disease (GVHD) or those with hematologic malignancies with prolonged neutropenia from chemotherapy [see Clinical Studies (14.1) ] as follows:...
Mechanism: Posaconazole is an azole antifungal agent [see Clinical Pharmacology (12.4) ] .
Therapeutic areas: Infectious disease and vaccines
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jan 27, 2026 Supplement 34 · Efficacy LetterLabel
- Sep 15, 2006 Original approval · Type 1 - New Molecular Entity · priority review NovelLabelReviewPediatric Medical Review
1 products under this application
- NOXAFIL · POSACONAZOLE 40MG/ML · SUSPENSION, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Posaconazole" as an intervention, any sponsor and status, largest first.
- Study of Biomarker-Based Treatment of Acute Myeloid LeukemiaPivotal-lookingRecruiting
Beat AML, LLCAcademic, hospital or other
NCT03013998 · 3,000 participants (planned) · Start Nov 2016 · Primary completion Dec 2032
Drug: Samalizumab (BAML-16-001-S1); BI 836858 (BAML-16-001-S2) and 45 more · For: Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
Sites: Phoenix, Arizona; Scottsdale, Arizona; Los Angeles, California · 31 sites in all
- Histoplasmosis Induction and Consolidation Therapy Factorial Randomized Clinical Trial (Histo-FACT)Pivotal-lookingNot yet recruiting
University of MinnesotaAcademic, hospital or other
NCT07261150 · 664 participants (planned) · Start Dec 1, 2026 · Primary completion Dec 31, 2030
Drug: LAmB B; Posaconazole and 2 more · For: Histoplasmosis
Sites: Minneapolis, Minnesota; Porto Alegre, Brazil
Sumitomo Pharma America, Inc.Industry
NCT04988555 · 606 participants (planned) · Start Feb 28, 2022 · Primary completion Jun 30, 2027
Drug: Enzomenib; azoles and 4 more · For: Leukemia, Myeloid, Acute; Leukemia, Lymphocytic, Acute; Multiple Myeloma and 1 more
Sites: Newport Beach, California; Palo Alto, California; Denver, Colorado · 104 sites in all
- Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow TransplantationPivotal-lookingCompleted
Mundipharma Research LimitedIndustry
NCT04368559 · 602 participants · Start May 11, 2020 · Primary completion Jan 29, 2026
Drug: Rezafungin for Injection; Posaconazole and 4 more · For: Candidemia; Mycoses; Fungal Infection and 7 more
Sites: Birmingham, Alabama; Los Angeles, California; Stanford, California · 53 sites in all
- Prophylaxis Trial of Posaconazole Versus Standard Azole Therapy for Neutropenic Patients (Study P01899)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT00044486 · 602 participants · Start Jul 2002 · Primary completion Dec 2004
Drug: Posaconazole oral suspension · For: Leukemia, Myelocytic, Acute; Myelodysplastic Syndromes; Neutropenia
- Prophylaxis Trial in High Risk Allogenic Stem Cell Transplant Recipients With Graft vs. Host DiseasePivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT00034645 · 600 participants · Start Jan 1999 · Primary completion Feb 2003
Drug: Posaconazole oral suspension · For: Mycoses
- A Study of the Safety and Efficacy of Posaconazole Versus Voriconazole for the Treatment of Invasive Aspergillosis (MK-5592-069)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT01782131 · 585 participants · Start Sep 25, 2013 · Primary completion Jul 10, 2019
Drug: Posaconazole; Voriconazole and 1 more · For: Fungal Infections; Invasive Pulmonary Aspergillosis
Schering-PloughMerck & Co. (MRK)
NCT00002399 · 500 participants
Drug: Posaconazole; Fluconazole · For: Candidiasis, Oral; HIV Infections
Sites: Tucson, Arizona; Jonesboro, Arkansas; Miami, Florida · 53 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use1,706
- drug ineffective1,513
- febrile neutropenia1,099
- product use in unapproved indication1,074
- drug interaction1,042
- death993
- pyrexia921
- neutropenia770
- pneumonia698
- thrombocytopenia551
- diarrhoea550
- nausea536
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 3 |
| 2005 | 22 |
| 2006 | 33 |
| 2007 | 113 |
| 2008 | 116 |
| 2009 | 154 |
| 2010 | 115 |
| 2011 | 182 |
| 2012 | 249 |
| 2013 | 249 |
| 2014 | 407 |
| 2015 | 503 |
| 2016 | 631 |
| 2017 | 930 |
| 2018 | 1,101 |
| 2019 | 1,229 |
| 2020 | 1,363 |
| 2021 | 1,534 |
| 2022 | 1,529 |
| 2023 | 1,576 |
| 2024 | 1,684 |
| 2025 | 1,671 |
| 2026 | 1,170 |
Recalls
1 FDA enforcement reports for this application.
Dec 12, 2025 · Class II · Ongoing
Presence of particulate matter: potential presence of metal particulates in the product.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Noxafil* (Posaconazole)
2024 spending
$632K
Beneficiaries
84
146 claims
Per beneficiary
$7,530
$58.66 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $15,485,827 |
| 2021 | $7,985,674 |
| 2022 | $5,375,749 |
| 2023 | $2,509,595 |
| 2024 | $632,487 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Candida auris-a systematic review to inform the world health organization fungal priority pathogens list.
Kim HY, Nguyen TA, Kidd S, et al. · Med Mycol 2024 · Systematic Review
- Candidiasis (oropharyngeal).
Pankhurst CL · BMJ Clin Evid 2013 · Systematic Review
- Candidiasis (oropharyngeal).
Pankhurst CL · BMJ Clin Evid 2012 · Systematic Review
- Cryptococcosis-a systematic review to inform the World Health Organization Fungal Priority Pathogens List.
Dao A, Kim HY, Garnham K, et al. · Med Mycol 2024 · Systematic Review
- Aspergillus fumigatus-a systematic review to inform the World Health Organization priority list of fungal pathogens.
Morrissey CO, Kim HY, Duong TN, et al. · Med Mycol 2024 · Systematic Review
- Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial.
Maertens JA, Rahav G, Lee DG, et al. · Lancet 2021 · Clinical Trial, Phase III, Multicenter Study
Sponsor: Merck & Co.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.